Literature DB >> 21532539

FDG- and amyloid-PET in Alzheimer's disease: is the whole greater than the sum of the parts?

L Mosconi1, P F McHugh.   

Abstract

The development of prevention therapies for Alzheimer's disease (AD) would greatly benefit from biomarkers that are sensitive to subtle brain changes occurring prior to the onset of clinical symptoms, when the potential for preservation of function is at the greatest. In vivo brain imaging is a promising tool for the early detection of AD through visualization of abnormalities in brain structure, function and histopathology. Currently, positron emission tomography (PET) imaging with amyloid-beta (Aβ) tracers and 2-[(18)F]fluoro-2-Deoxy-D-glucose (FDG) is largely utilized in the diagnosis of AD. This paper reviews brain Aβ- and FDG-PET studies in AD patients as well as in non-demented individuals at risk for AD. We then discuss the potential of combining symptoms-sensitive FDG-PET measures with pathology-specific Aβ-PET to improve the early detection of AD.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21532539      PMCID： PMC3290913     

Source DB:  PubMed          Journal:  Q J Nucl Med Mol Imaging        ISSN： 1824-4785            Impact factor:   2.346


  117 in total

1.  Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease?

Authors:  G Chételat; B Desgranges; V de la Sayette; F Viader; F Eustache; J-C Baron
Journal:  Neurology       Date:  2003-04-22       Impact factor: 9.910

2.  Hippocampal hypometabolism predicts cognitive decline from normal aging.

Authors:  Lisa Mosconi; Susan De Santi; Juan Li; Wai Hon Tsui; Yi Li; Madhu Boppana; Eugene Laska; Henry Rusinek; Mony J de Leon
Journal:  Neurobiol Aging       Date:  2007-01-11       Impact factor: 4.673

3.  Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment.

Authors:  R D Terry; E Masliah; D P Salmon; N Butters; R DeTeresa; R Hill; L A Hansen; R Katzman
Journal:  Ann Neurol       Date:  1991-10       Impact factor: 10.422

4.  Dissociation of neuropathology from severity of dementia in late-onset Alzheimer disease.

Authors:  I Prohovnik; D P Perl; K L Davis; L Libow; G Lesser; V Haroutunian
Journal:  Neurology       Date:  2006-01-10       Impact factor: 9.910

Review 5.  Expanding the association between the APOE gene and the risk of Alzheimer's disease: possible roles for APOE promoter polymorphisms and alterations in APOE transcription.

Authors:  Simon M Laws; Eugene Hone; Sam Gandy; Ralph N Martins
Journal:  J Neurochem       Date:  2003-03       Impact factor: 5.372

6.  Development of Alzheimer-related neurofibrillary changes in the neocortex inversely recapitulates cortical myelogenesis.

Authors:  H Braak; E Braak
Journal:  Acta Neuropathol       Date:  1996-08       Impact factor: 17.088

7.  Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease.

Authors:  P V Arriagada; K Marzloff; B T Hyman
Journal:  Neurology       Date:  1992-09       Impact factor: 9.910

8.  Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees.

Authors:  William E Klunk; Julie C Price; Chester A Mathis; Nicholas D Tsopelas; Brian J Lopresti; Scott K Ziolko; Wenzhu Bi; Jessica A Hoge; Ann D Cohen; Milos D Ikonomovic; Judith A Saxton; Beth E Snitz; Daniel A Pollen; Majaz Moonis; Carol F Lippa; Joan M Swearer; Keith A Johnson; Dorene M Rentz; Alan J Fischman; Howard J Aizenstein; Steven T DeKosky
Journal:  J Neurosci       Date:  2007-06-06       Impact factor: 6.167

9.  Brain imaging evidence of preclinical Alzheimer's disease in normal aging.

Authors:  William Jagust; Amy Gitcho; Felice Sun; Beth Kuczynski; Dan Mungas; Mary Haan
Journal:  Ann Neurol       Date:  2006-04       Impact factor: 10.422

10.  Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease.

Authors:  Yi Li; Juha O Rinne; Lisa Mosconi; Elizabeth Pirraglia; Henry Rusinek; Susan DeSanti; Nina Kemppainen; Kjell Någren; Byeong-Chae Kim; Wai Tsui; Mony J de Leon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-06-20       Impact factor: 9.236
View more
  21 in total

Review 1.  Glucose Transporters at the Blood-Brain Barrier: Function, Regulation and Gateways for Drug Delivery.

Authors:  Simon G Patching
Journal:  Mol Neurobiol       Date:  2016-01-22       Impact factor: 5.590

2.  Modulation of glucose metabolism and metabolic connectivity by β-amyloid.

Authors:  Felix Carbonell; Alex P Zijdenbos; Donald G McLaren; Yasser Iturria-Medina; Barry J Bedell
Journal:  J Cereb Blood Flow Metab       Date:  2016-06-14       Impact factor: 6.200

Review 3.  Promise, Progress, and Pitfalls in the Search for Central Nervous System Biomarkers in Neuroimmunological Diseases: A Role for Cerebrospinal Fluid Immunophenotyping.

Authors:  Bibiana Bielekova; Michael R Pranzatelli
Journal:  Semin Pediatr Neurol       Date:  2017-08-12       Impact factor: 1.636

4.  Enhancement of Partial Volume Correction in MR-Guided PET Image Reconstruction by Using MRI Voxel Sizes.

Authors:  Martin A Belzunce; Abolfazl Mehranian; Andrew J Reader
Journal:  IEEE Trans Radiat Plasma Med Sci       Date:  2018-11-15

Review 5.  Estrogen regulation of mitochondrial bioenergetics: implications for prevention of Alzheimer's disease.

Authors:  Jia Yao; Roberta Diaz Brinton
Journal:  Adv Pharmacol       Date:  2012

6.  T3D-959: A Multi-Faceted Disease Remedial Drug Candidate for the Treatment of Alzheimer's Disease.

Authors:  Ming Tong; Chetram Deochand; John Didsbury; Suzanne M de la Monte
Journal:  J Alzheimers Dis       Date:  2016       Impact factor: 4.472

Review 7.  Is MRI better than CT for detecting a vascular component to dementia? A systematic review and meta-analysis.

Authors:  Rebecca Beynon; Jonathan A C Sterne; Gordon Wilcock; Marcus Likeman; Roger M Harbord; Margaret Astin; Margaret Burke; Alysson Bessell; Yoav Ben-Shlomo; James Hawkins; William Hollingworth; Penny Whiting
Journal:  BMC Neurol       Date:  2012-06-06       Impact factor: 2.474

8.  Longitudinal Characterization of [18F]-FDG and [18F]-AV45 Uptake in the Double Transgenic TASTPM Mouse Model.

Authors:  Ann-Marie Waldron; Leonie Wyffels; Jeroen Verhaeghe; Jill C Richardson; Mark Schmidt; Sigrid Stroobants; Xavier Langlois; Steven Staelens
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

9.  β-Amyloid is associated with aberrant metabolic connectivity in subjects with mild cognitive impairment.

Authors:  Felix Carbonell; Arnaud Charil; Alex P Zijdenbos; Alan C Evans; Barry J Bedell
Journal:  J Cereb Blood Flow Metab       Date:  2014-04-16       Impact factor: 6.200

10.  Targeting Alzheimer's Disease Neuro-Metabolic Dysfunction with a Small Molecule Nuclear Receptor Agonist (T3D-959) Reverses Disease Pathologies.

Authors:  Ming Tong; Cesar Dominguez; John Didsbury; Suzanne M de la Monte
Journal:  J Alzheimers Dis Parkinsonism       Date:  2016-06-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.